News | June 03, 2026
Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
Transition to a fermentation-based globally integrated CDMO platform
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Subscribe To Our Newsletter & Stay Updated
